BioCentury
ARTICLE | Company News

Janssen snaps up Alligator's immunotherapy candidate

August 13, 2015 1:46 AM UTC

Alligator Bioscience AB (Lund, Sweden) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to cancer immunotherapy candidate ADC-1013. Under a separate agreement, J&J's venture arm Johnson & Johnson Innovation-JJDC Inc. will make an equity investment in Alligator.

Alligator said it is eligible for a total of $700 million, including an upfront payment and milestones, plus royalties. J&J spokesperson Ellen Rose said the $700 million also includes the JJDC investment, but declined to provide further details. Alligator did not respond to inquiries. ...